Timothy G. Majors
100 IP cases indexed. Covers patent matters.
Cases Presided Over
100 cases indexed | Page 2 of 4
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s U.S. Patent 12,016,580 covering intravascular embolism treatment devices after finding Imperative Care’s obviousness arguments sufficiently promising.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR against Inari Medical’s 12,016,580 hemostasis valve patent, finding a reasonable likelihood that Imperative Care will prevail on at least one of the nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success sufficient. All nine claims are now under trial.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products, Inc.'s IPR petition against Solmetex, LLC's dental device patent was denied by the PTAB. The Board ruled that Petitioner failed to provide sufficient evidence regarding obviousness over prior art references like Black and Park/Baughan/Johnson.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
The PTAB denied Ascentcare Dental Products' IPR petition against Solmetex, LLC's dental device patent due to procedural timing issues. The Board found the patent was a post-AIA patent and the petition was filed too early.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable, finding anticipation and obviousness over Schaffer and combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. The review will cover claims 1‑9 and is based on anticipation and obviousness grounds over Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent covering claims 1‑9. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness over Schaffer and related references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care's petition to institute an IPR against Inari Medical's embolism‑treatment patent, finding no reasonable likelihood of success on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB institution decision in this IPR found that the petitioner met its burden of showing a reasonable likelihood of prevailing on at least claim 1. The dispute centers on obviousness (35 U.S.C. § 103) regarding medical devices used for aspirating clot material from blood vessels.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
In an IPR, the PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable under §§102 and 103, finding the petitioner’s anticipation and obviousness arguments persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care’s petition to review Inari Medical’s 11,744,691 patent covering catheter‑based embolism removal. The Board found the petitioner had not shown a reasonable likelihood of prevailing on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent, covering claims 1‑9, on grounds of anticipation and obviousness.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent after Imperative Care demonstrated a reasonable likelihood of unpatentability on claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering a vacuum aspiration system with hemostasis valve. Petitioner Imperative Care showed a reasonable likelihood of prevailing on at least one claim, especially claim 1, based on obviousness over Garrison, Schaffer and other references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully met the institution burden in its IPR against Inari Medical's '333 patent, establishing a reasonable likelihood of prevailing on key claims. The Board found that combining prior art references like Laub and Garrison renders the claimed thromboembolism treatment systems obvious under 103.
Valneva Austria GMBH v.Takeda Vaccines, Inc.
Valneva Austria and Takeda Vaccines jointly moved to terminate an IPR covering 67 vaccine‑related claims. The Board granted the motion, dismissing the petition without a merits decision.
Valneva Austria GMBH v.Takeda Vaccines, Inc.
Valneva Austria GMBH successfully convinced the PTAB to institute IPR proceedings against Takeda Vaccines regarding a vaccine patent. The Board found a reasonable likelihood that several claims are unpatentable over combinations of prior art, specifically citing evidence related to fetal protection and antibody transfer.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 patent covering hemostasis valves after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted inter partes review on all 15 claims of Inari Medical’s embolism‑treatment patent after finding Imperative Care’s obviousness arguments sufficiently persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s ’291 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All 16 challenged claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim. All nine claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation by Schaffer and obviousness over combinations with Hartley, Eller and Garrison. The decision hinges on the Board’s construction that the claimed filament must be flexible, which the prior art does not disclose.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted Imperative Care’s petition to institute inter partes review of Inari Medical’s hemostasis‑valve patent, finding a reasonable likelihood of unpatentability for claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care's petition to institute an IPR against Inari Medical's embolism‑treatment patent, finding no reasonable likelihood of unpatentability. The petition relied on anticipation and obviousness over Garrison and other references, but lacked sufficient particularity.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care proved all nine claims of Inari Medical’s 11,697,011 B2 hemostasis valve patent are unpatentable, finding the term “filament” must be flexible and that the prior art renders the claims obvious.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB decided to institute trial on all challenged claims of the '921 patent, despite preliminary evidence not supporting anticipation over Schaffer. The Board adopted a broad definition of 'filament' but ultimately found that the claim language required flexibility based on intrinsic and extrinsic teachings.
CSPC Pharmaceutical Group Limited et al. v.Ipsen Biopharm Ltd. et al.
The PTAB institution decision in this oncology IPR upheld the patent claims against numerous prior art references related to FOLFIRINOX and nanoliposomal irinotecan. The Board adopted a specific claim construction defining 'treatment' as requiring more than a de minimis therapeutic benefit for the patient.
Padagis US LLC et al. v.Neurelis, Inc.
Padagis US LLC successfully challenged Neurelis, Inc.'s patent claims covering nasal drug delivery formulations. The Board found a reasonable likelihood of prevailing on multiple grounds, leading to the institution of the IPR.
Padagis US LLC et al. v.Neurelis, Inc.
Padagis US LLC successfully challenged claims 1-18 of Neurelis, Inc.'s patent under grounds of obviousness (103) and lack of written description (102). The Board found a reasonable likelihood that the invention is unpatentable, based on combining prior art references Gwozdz and Meezan.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.